Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 71% · refreshes every 15s during session
Aktis Oncology, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence, with mixed management execution.
Why it matters: Revenue +111% YoY in Q2 FY2026.
2 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 0d ago
AKTS's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on AKTS.
Free accounts see more of this; Premium sees all of it.
Reported figures for Aktis Oncology, Inc. — research only, not investment advice.
Updated
What happened recently for Aktis Oncology, Inc. (AKTS) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
Investment snapshot
AKTS's AI investment thesis
Upgrade to Premium for AKTS's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Latest price
$19.43
Market cap
$1.01B
Profitable
No
Revenue $3.23M
Net income
$-18.33M
FY Sep 15, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Aktis Oncology, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Aktis Oncology, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.